Potentials of Differentiated Human Cord Blood-Derived Unrestricted Somatic Stem Cells in Treatment of Liver Cirrhosis

Baz, Hanan El; Demerdash, Zeinab; Kamel, Manal; Atta, Shimaa; Salah, Faten; Hassan, S. S.; Hammam, Olfat; Khalil, Heba; Bayoumi, Ali

doi:10.6002/ect.2017.0249

Cited by 4 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior studies have shown that HUCB-MSCs can safely and effectively improve liver function as shown by improvements to Child-Turcotte-Pugh (CTP) and model for end-stage liver disease (MELD) scores in patients with liver cirrhosis. 15 , 16 However, there is a lack of data on the long-term efficacy of umbilical cord mesenchymal stem cell transplantation, particularly in patients with liver cirrhosis. Moreover, transplantation of stem cells also carries safety risks such as the potential for tumor development.…”

Section: Introductionmentioning

confidence: 99%

Human Umbilical Cord Blood-Derived Mesenchymal Stem Cell Transplantation for Patients with Decompensated Liver Cirrhosis

Zhou

Han

et al. 2023

Journal of Gastrointestinal Surgery

View full text Add to dashboard Cite

Background or Purpose Although human umbilical cord blood-derived mesenchymal stem cell transplantation (HUCB-MSCT) resulted in a good short-term therapeutic effect on patients with decompensated liver cirrhosis (DLC), the long-term survival remained unclear. This study aimed to evaluate the impact of HUCB-MSCT on long-term outcomes in patients with DLC. Methods This retrospective cohort study included hospitalized patients with decompensated cirrhosis in Liuzhou Hospital of Traditional Chinese Medicine between November 2010 and February 2013. The primary outcome was overall survival (OS). The secondary outcomes were 3-year and 5-year survival rates and the occurrence rate of hepatocellular carcinoma (HCC). Results A total of 201 subjects were enrolled, including 36 patients who underwent HUCB-MSCT (SCT group) and 165 patients who did not (non-SCT group). After PSM (1:2), there were 36 patients in the SCT group and 72 patients in non-SCT group. The 3-year and 5-year survival rates of the two groups were 83.3% vs. 61.8% and 63.9% vs. 43.6%, and median OS time was 92.50 and 50.80 months, respectively. HUCB-MSCT treatment was found to be an independent beneficial factor for patient OS (hazard ratio = 0.47; 95% CI: 0.29–0.76; P = 0.002). There was no significant difference in the occurrence rate of HCC between the two groups (P = 0.410). Discussion or Conclusions HUCB-MSCT may improve long-term OS without increasing the occurrence of HCC in patients with DLC. Trial Registration The Chinese Clinical Trial Registry (ChiCTR2100047550).

show abstract

Section: Introductionmentioning

confidence: 99%

Human Umbilical Cord Blood-Derived Mesenchymal Stem Cell Transplantation for Patients with Decompensated Liver Cirrhosis

Zhou

Han

et al. 2023

Journal of Gastrointestinal Surgery

View full text Add to dashboard Cite

show abstract

“…There are several animal models and human studies that use various types of MSCs to ameliorate different types of liver injury in both acute and chronic liver disease. [ 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 ]…”

Section: Introductionmentioning

confidence: 99%

“…There are several animal models and human studies that use various types of MSCs to ameliorate different types of liver injury in both acute and chronic liver disease. [5][6][7][8][9][10][11][12][13][14][15] MSCs derived from mouse bone marrow injected intraperitoneally demonstrated reduced liver steatosis, oxidative stress, and inflammatory cell infiltration. [13] Additional studies have demonstrated improvement in hepatic chemistries including alanine transaminase (ALT), aspartate transaminase (AST), and steatosis, and had an anti-inflammatory effect.…”

Section: Introductionmentioning

confidence: 99%

Activated and nonactivated MSCs increase survival in humanized mice after acute liver injury through alcohol binging

Hernandéz

Yeh

Marh³

et al. 2022

Hepatol Commun

View full text Add to dashboard Cite

The ability of the liver to regenerate after injury makes it an ideal organ to study for potential therapeutic interventions. Mesenchymal stem cells (MSCs) possess self-renewal and differentiation properties, as well as anti-inflammatory properties that make them an ideal candidate for therapy of acute liver injury. The primary aim of this study is to evaluate the potential for reversal of hepatic injury using human umbilical cord-derived MSCs. Secondary aims include comparison of various methods of administration as well as comparison of activated versus nonactivated human umbilical cord stem cells. To induce liver injury, humanized mice were fed high-cholesterol high-fat liquid diet with alcohol binge drinking. Mice were then treated with either umbilical cord MSCs, activated umbilical cord MSCs, or a placebo and followed for survival. Blood samples were obtained at the end of the binge drinking and at the time of death to measure alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. Histology of all mouse livers was reported at time of death. Activated MSCs that were injected intravenously, intraperitoneally, or both routes had superior survival compared with nonactivated MSCs and with placebo-treated mice. AST and ALT levels were elevated in all mice before treatment and improved in the mice treated with stem cells. Conclusion:Activated stem cells resulted in marked improvement in survival and in recovery of hepatic chemistries. Activated umbilical cord MSCs should be considered an important area of investigation in acute liver injury.

show abstract

Liver regeneration after injury: Mechanisms, cellular interactions and therapeutic innovations

Liu,

Wang,

et al. 2024

Clinical & Translational Med

View full text Add to dashboard Cite

The liver possesses a distinctive capacity for regeneration within the human body. Under normal circumstances, liver cells replicate themselves to maintain liver function. Compensatory replication of healthy hepatocytes is sufficient for the regeneration after acute liver injuries. In the late stage of chronic liver damage, a large number of hepatocytes die and hepatocyte replication is blocked. Liver regeneration has more complex mechanisms, such as the transdifferentiation between cell types or hepatic progenitor cells mediated. Dysregulation of liver regeneration causes severe chronic liver disease. Gaining a more comprehensive understanding of liver regeneration mechanisms would facilitate the advancement of efficient therapeutic approaches. This review provides an overview of the signalling pathways linked to different aspects of liver regeneration in various liver diseases. Moreover, new knowledge on cellular interactions during the regenerative process is also presented. Finally, this paper explores the potential applications of new technologies, such as nanotechnology, stem cell transplantation and organoids, in liver regeneration after injury, offering fresh perspectives on treating liver disease.

show abstract

Potentials of Differentiated Human Cord Blood-Derived Unrestricted Somatic Stem Cells in Treatment of Liver Cirrhosis

Cited by 4 publications

References 26 publications

Human Umbilical Cord Blood-Derived Mesenchymal Stem Cell Transplantation for Patients with Decompensated Liver Cirrhosis

Human Umbilical Cord Blood-Derived Mesenchymal Stem Cell Transplantation for Patients with Decompensated Liver Cirrhosis

Activated and nonactivated MSCs increase survival in humanized mice after acute liver injury through alcohol binging

Liver regeneration after injury: Mechanisms, cellular interactions and therapeutic innovations

Contact Info

Product

Resources

About